赛诺医疗(688108.SH)公告称,公司自主研发的TRADENTTM冠状动脉棘突球囊扩张导管获得泰国食品药品监督管理局的批准,在泰国获得《医疗器械注册证》。该产品主要用于PTCA中对于血管狭窄病变进行扩张治疗。这是该产品在海外取得的第一张注册证,将有效增加公司海外业务的在售产品品类
赛诺医疗(688108.SH)公告称,公司自主研发的TRADENTTM冠状动脉棘突球囊扩张导管获得泰国食品药品监督管理局的批准,在泰国获得《医疗器械注册证》。该产品主要用于PTCA中对于血管狭窄病变进行扩张治疗。这是该产品在海外取得的第一张注册证,将有效增加公司海外业务的在售产品品类
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.